The unusual intense coverage of a new study showing benefits of the Pfizer antiviral drug Paxlovid can best be explained by the collusion between the media and the big drug industry. In its 2022 financial guidance, the company reported Paxlovid revenue of $22 billion. True, the new data are impressive in some ways. But some… Read More »Paxlovid Hype About Long COVID
